IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
Brian I. Rini(Vanderbilt University Medical Center), Tim Eisen(Royal Marsden Hospital), Carsten Reinhardt(Immatics Biotechnologies (Germany)), Regina Mendrzyk(Immatics Biotechnologies (Germany)), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Sergio Bracarda(Azienda Ospedaliera S.Maria), Harpreet Singh‐Jasuja(Immatics Biotechnologies (Germany)), Claudia Wagner(Immatics Biotechnologies (Germany)), Romauld Zdrojowy(Wroclaw Medical University), Joerg Ludwig(Immatics Biotechnologies (Germany)), Simon J. Crabb(University of Southampton), М. И. Коган(Rostov State Medical University), Jens Bedke, Dominik Maurer(Immatics Biotechnologies (Germany)), Toni Weinschenk(Immatics Biotechnologies (Germany)), Jens Fritsche(Immatics Biotechnologies (Germany)), Arnulf Stenzl(University of Tübingen), Alexandra Kirner(Novartis (France)), Steffen Walter(Universität Ulm), Steffen Weikert(St. Hedwig-Krankenhaus), Andrea Mahr(Immatics Biotechnologies (Germany))
Cited by 218
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
|Journal of Clinical Oncology|2008|907
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803